+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030- Product Image
Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030- Product Image
Sale

Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010865
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Obstructive Pulmonary Disease Treatment Market grew from USD 83.39 billion in 2024 to USD 89.95 billion in 2025. It is expected to continue growing at a CAGR of 7.72%, reaching USD 130.34 billion by 2030.

Setting the Stage for COPD Treatment Innovations

Chronic obstructive pulmonary disease presents one of the most significant public health challenges of our time, manifesting in persistent respiratory symptoms, airflow limitation, and progressive lung function decline. As prevalence rises in correlation with aging populations and environmental pressures, the imperative for innovative treatment approaches intensifies. Healthcare providers, payers, and pharmaceutical developers are under pressure to deliver therapies that not only alleviate symptoms but also modify disease progression and improve quality of life for millions of patients worldwide.

Amid a complex ecosystem of drug classes and administration routes, a nuanced understanding of patient phenotypes, adherence drivers, and cost constraints becomes essential. This report delivers an executive summary that synthesizes the latest therapeutic developments, regulatory shifts, and competitive dynamics shaping the COPD landscape. By distilling multi-dimensional data into strategic takeaways, we aim to empower decision-makers with actionable insights that inform product positioning, investment priorities, and clinical program design.

Evolving Drivers Reshaping the COPD Market Landscape

The COPD market is undergoing a profound transformation driven by scientific breakthroughs, patient-centric care models, and evolving reimbursement paradigms. Breakthroughs in inhaled combination therapies that integrate corticosteroids with long-acting bronchodilators have reset the standard of care by delivering superior symptomatic relief and exacerbation reduction compared to monotherapies. In parallel, the advent of precision medicine tools is enabling phenotype-based treatment selection, targeting eosinophilic inflammation and genetic risk markers to tailor interventions more effectively.

Regulatory bodies are also adapting their frameworks to expedite access to therapies that demonstrate meaningful clinical benefit. Adaptive trial designs and real-world evidence are gaining acceptance as complementary sources of safety and efficacy data, accelerating product lifecycles and fostering competitive agility. Meanwhile, digital health platforms and connected inhalers are reshaping patient engagement by providing real-time adherence tracking and feedback, which in turn fuels data-driven care pathways. These convergent trends underscore the imperative for stakeholders to align R&D, regulatory strategy, and go-to-market execution around the twin goals of precision and patient empowerment.

Assessing the 2025 US Tariff Effects on COPD Therapies

The implementation of new tariff structures in 2025 has introduced substantive cost pressures on imported pharmaceuticals, prompting manufacturers to reassess supply chain configurations and sourcing strategies. Tariffs levied on critical active pharmaceutical ingredients and finished inhalation devices translate directly into higher unit costs, which risk impairment of already thin payer margins. In response, several leading companies have initiated near-shoring efforts, relocating key manufacturing steps to domestic facilities to mitigate tariff exposure and protect competitive pricing.

At the same time, pricing negotiations with government payers have intensified, as cost increases reverberate through hospital formularies and retail channels. Some organizations are exploring alternative contracting models, including value-based arrangements that link reimbursement to patient outcomes, thereby diffusing the impact of upfront tariff-induced price escalations. Amid these dynamics, strategic alliances between global and local players are becoming more prevalent, with co-development agreements and joint ventures serving as vehicles to share risk, optimize cost structures, and maintain access to essential COPD therapies.

Unpacking Multifaceted Segmentation Patterns in COPD Treatment

An in-depth segmentation analysis illuminates the multifaceted competitive terrain of COPD treatment. A product type lens reveals a spectrum that spans antibiotics and corticosteroids, with an increasing focus on combination therapies such as ICS plus LABA, ICS plus LABA plus LAMA, and LABA plus LAMA, all of which are capturing physician preference for their synergistic efficacy. Examining the market by drug class uncovers the rising prominence of anticholinergics and phosphodiesterase-4 inhibitors, while long-acting beta agonists and short-acting beta agonists continue to play foundational roles in symptom management.

Route of administration further differentiates therapeutic profiles: inhalation dominates through formats like dry powder inhalers, metered-dose inhalers, and nebulizers, while oral and intravenous options serve specific patient cohorts with acute exacerbations or co-morbid conditions. Distribution channel analysis highlights the balancing act between hospital pharmacies, which deliver acute care therapies, and retail and online pharmacies that support home-based maintenance regimens. Finally, therapy type segmentation underscores the strategic divide between maintenance treatments engineered for long-term disease control and rescue therapies that address acute airflow obstruction episodes. This layered segmentation framework equips stakeholders to align R&D pipelines, marketing strategies, and distribution networks with the nuanced needs of diverse patient segments.

Regional Dynamics Shaping Global COPD Treatment Strategies

Regional dynamics play a pivotal role in shaping competitive strategies and access models for COPD therapies. In the Americas, a robust private payer ecosystem coexists with public insurance programs, driving manufacturers to tailor patient assistance initiatives and targeted contracting with integrated delivery networks to maximize formulary placement. Meanwhile, pricing scrutiny and value-based care pilots in the United States have spurred the creation of outcome-linked rebate agreements that anchor reimbursement to exacerbation reduction and hospital readmission rates.

Across Europe, the Middle East & Africa, diverse regulatory frameworks and purchasing consortia influence market access timelines. In Western Europe, centralized health technology assessments prioritize cost-effectiveness metrics, favoring therapies that demonstrate long-term health-economic benefits. In contrast, several Middle Eastern countries employ rapid approval pathways and volume-based procurement to secure generics and biosimilars at scale. Africa’s nascent infrastructure presents challenges in distribution and cold-chain logistics, yet it also offers growth potential through public-private partnerships aimed at expanding diagnostic capabilities.

The Asia-Pacific region embodies heterogeneity in payer maturation, from advanced digital health integration in Australia to evolving reimbursement platforms in emerging Southeast Asian markets. Governments are increasingly investing in air quality initiatives and early screening programs, which in turn elevate demand for maintenance therapies. The confluence of these regional factors underscores the importance of geotargeted launch strategies and flexible manufacturing footprints to address local access barriers and patient needs.

Leading Industry Players Steering the COPD Market Forward

The competitive landscape features a blend of established pharmaceutical giants and agile specialized biotech firms, each vying for therapeutic leadership. Multinational companies with broad respiratory portfolios leverage vast clinical trial networks and global distribution channels to accelerate development timelines and drive market penetration. Their scale enables significant investment in late-stage pipeline assets, including novel inhaled triple therapies and biologics targeting inflammatory pathways.

Conversely, nimble biotechnology enterprises focus on niche differentiation, advancing inhalation device innovations, digital therapeutics, and targeted small molecules that address unmet phenotypes. Collaboration between large and small players has become a defining feature, with licensing agreements and co-development deals facilitating technology transfer and shared risk. Contract manufacturing organizations have also gained prominence, supplying specialized fill-finish capabilities that are critical for complex inhaled formulations. Together, these ecosystem participants shape a dynamic market environment where scientific innovation and strategic partnerships determine leadership positions.

Strategic Actions to Capitalize on Emerging COPD Trends

Industry leaders should prioritize an integrated strategy that spans R&D, regulatory engagement, and commercialization excellence. Early incorporation of real-world evidence into clinical programs can validate product differentiation and support favorable health authority interactions. Embracing adaptive trial designs will enable more efficient evaluation of combination therapies and targeted biologics, accelerating time to regulatory submission.

From a commercial standpoint, forging value-based contracts with payers and providers will mitigate pricing pressures exacerbated by tariff impacts. Investments in connected inhalation platforms and patient support programs will drive adherence, generating outcome data that reinforce product value. Geographic expansion plans should align manufacturing placement with regional tariff landscapes and supply chain contingencies, ensuring continuity of supply and competitive cost structures.

Finally, cultivating cross-sector partnerships-linking scientific institutions, digital health innovators, and payer networks-will enhance patient engagement and streamline care pathways. By embedding collaborative models throughout the product lifecycle, companies can achieve accelerated market access, improved health outcomes, and sustainable growth in the evolving COPD therapeutics arena.

Rigorous Methodology Underpinning Market Insights

This analysis is grounded in a rigorous, multi-source research framework designed to ensure robust and unbiased insights. Primary research included in-depth interviews with key opinion leaders across pulmonology, pharmacy, and payer communities, alongside advisory board consultations. Secondary research encompassed peer-reviewed journals, regulatory filings, industry conference proceedings, and white papers from reputable healthcare organizations.

Competitive intelligence was gathered through analysis of patent filings, clinical trial registries, and corporate press releases. Pricing and reimbursement data were synthesized from government databases and public tender announcements. Regional market dynamics were validated through local expert panels, ensuring nuanced understanding of policy and access variations. A structured data triangulation process was applied to reconcile disparate information sources, enhancing the credibility and relevance of our findings.

Throughout the research process, methodological rigor was maintained via quality control protocols, including source verification, consistency checks, and peer review by subject matter experts. The resulting insights reflect a holistic view of the COPD treatment landscape, equipping stakeholders with the evidence base required to inform strategic decisions and drive value creation.

Synthesizing Insights for Sustainable COPD Management

The complexities inherent in COPD therapy development and commercialization demand a synthesis of scientific innovation, strategic foresight, and collaborative execution. By integrating advancements in inhaled modalities with data-driven patient stratification, stakeholders can deliver more precise and impactful interventions. Navigating evolving tariff environments and reimbursement reforms requires agile supply chain strategies and outcome-based contracting frameworks that align stakeholder incentives.

Regional nuances-from payer maturity to regulatory pathways-underscore the necessity of geotargeted launch plans that respect local access imperatives while leveraging global scale. Meanwhile, partnerships across the pharmaceutical, biotech, and digital health sectors will catalyze new care delivery models and accelerate adoption of value-added therapies. Ultimately, sustained progress in COPD management hinges on a balanced focus on clinical efficacy, economic value, and patient empowerment. The insights presented here offer a strategic roadmap for organizations committed to shaping the future of COPD treatment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Antibiotics
    • Combination Therapies
      • Ics + Laba
      • Ics + Laba + Lama
      • Laba + Lama
    • Corticosteroids
    • Long Acting Bronchodilators
    • Phosphodiesterase Four Inhibitors
    • Short Acting Bronchodilators
  • Drug Class
    • Anticholinergics
    • Beta Agonists
      • Long Acting Beta Agonists
      • Short Acting Beta Agonists
    • Corticosteroids
    • Methylxanthines
    • Phosphodiesterase Four Inhibitors
  • Route Of Administration
    • Inhalation
      • Dry Powder Inhaler
      • Metered Dose Inhaler
      • Nebulizer
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Therapy Type
    • Maintenance
    • Rescue
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Sandoz International GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Obstructive Pulmonary Disease Treatment Market, by Product Type
8.1. Introduction
8.2. Antibiotics
8.3. Combination Therapies
8.3.1. Ics + Laba
8.3.2. Ics + Laba + Lama
8.3.3. Laba + Lama
8.4. Corticosteroids
8.5. Long Acting Bronchodilators
8.6. Phosphodiesterase Four Inhibitors
8.7. Short Acting Bronchodilators
9. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Class
9.1. Introduction
9.2. Anticholinergics
9.3. Beta Agonists
9.3.1. Long Acting Beta Agonists
9.3.2. Short Acting Beta Agonists
9.4. Corticosteroids
9.5. Methylxanthines
9.6. Phosphodiesterase Four Inhibitors
10. Chronic Obstructive Pulmonary Disease Treatment Market, by Route of Administration
10.1. Introduction
10.2. Inhalation
10.2.1. Dry Powder Inhaler
10.2.2. Metered Dose Inhaler
10.2.3. Nebulizer
10.3. Intravenous
10.4. Oral
11. Chronic Obstructive Pulmonary Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Chronic Obstructive Pulmonary Disease Treatment Market, by Therapy Type
12.1. Introduction
12.2. Maintenance
12.3. Rescue
13. Americas Chronic Obstructive Pulmonary Disease Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. GlaxoSmithKline plc
16.3.2. AstraZeneca plc
16.3.3. Boehringer Ingelheim International GmbH
16.3.4. Novartis AG
16.3.5. Teva Pharmaceutical Industries Limited
16.3.6. Viatris Inc.
16.3.7. Chiesi Farmaceutici S.p.A.
16.3.8. Cipla Limited
16.3.9. Sun Pharmaceutical Industries Limited
16.3.10. Sandoz International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ICS + LABA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ICS + LABA + LAMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LABA + LAMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 63. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 112. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 114. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 138. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 140. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 144. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 146. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 176. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 192. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 226. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 232. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 234. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 244. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 250. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 254. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2030 (USD MILLION)
TABLE 256. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Obstructive Pulmonary Disease Treatment market report include:
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 89.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 130.34 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2025 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 343 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.